Curexo Inc (060280) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Curexo Inc stock KRW 846, price KRW 6,570, that is 87.1% below the price, quality 61 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 5,610 KRW – 24,400 KRW · fair‑value band 806.28 KRW – 878.19 KRW · the 6,570 KRW price screens above the 846.16 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Curexo in your weekly email
Every Wednesday you see whether Curexo is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Curexo Inc. engages in the development and sale of medical devices in Korea and internationally.
Show moreShow less
Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot.
The company also imports, distributes, and sells food and food additives. Curexo Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Stock analysis
Curexo Inc (060280) currently trades at 6,570 KRW, while our model-based Fair Value estimate is 846.16 KRW, 87% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 2,001 KRW per share, and 1 of the 15 models we run sit above the 6,570 KRW price.
Bear case: the DCF Models group reads lowest at 544.63 KRW, and 14 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: 806.28 KRW (bear) to 878.19 KRW (bull), the price of 6,570 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Consumer Non-Cyclicals sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Curexo Inc reported revenue of 74.5B KRW in FY2025 versus 42.8B KRW in FY2021, a compound +14.9%/yr. Reported net income was 2.8B KRW in FY2025.
Key figures
Market cap 306B KRW (≈ $224M) Micro · P/S ratio 11.0 · Net margin −58.0% · Return on equity −744% · Return on assets (EBIT) −2.2% (5-year average) · Operating margin −153% · Revenue (TTM) 27.8B KRW · Revenue growth (YoY) +4.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (medium confidence).
What moves the price
The share trades about 68% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −3% fair-value upside, at −87%, 060280 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (441.12 KRW to 9,690 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear806.28 KRWFair Value 846.16 KRWBull878.19 KRW
Price 6,570 KRW · Downside -87.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+34.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +10.5% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+40.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+40.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.40.2% vs −22.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 3%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Food & Drug Retailing” was too small, so the broader sector is used.)Health Care · 2277 stocks
Beats the sector median on 2/8 measures
Overall it trails its sector peers.
Valuation
Quality Score61 · Above median
Fair Value upside−87.1% · Bottom 25%
Profitability
Return on assets2.7% · Above median
Net margin (12 months)3.7% · Below median
Operating margin (12 months)−152.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)4.3% · Below median
Valuation Multiplesvs Health Care median · lower = cheaper
P/B3.18× · Pricier than median
P/S (12 months)10.98× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)22· sector 31
PAST (return on equity)0· sector 18
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Curexo Inc Fair Value". https://www.fairvalue-calculator.com/stock/060280
Frequently asked questions
Is Curexo Inc (060280) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 846.16 KRW versus a price of 6,570 KRW, about 87% lower (overvalued).
What is the fair value of 060280?
Our model-based fair value for Curexo Inc is 846.16 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 6,570 KRW.
What is the quality score of 060280?
Curexo Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Curexo Inc (060280)?
Our model-based price target is the fair value of 846.16 KRW (as of Nov 7, 2026) from 15 valuation models. Cautious scenario 806.28 KRW, optimistic scenario 878.19 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Curexo Inc stock forecast for 2026?
Our models put fair value at 846.16 KRW, about 87% lower versus a price of 6,570 KRW (overvalued). Cautious scenario 806.28 KRW, optimistic scenario 878.19 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Curexo Inc (060280)?
Curexo Inc reported trailing-twelve-month revenue of about 27.8B KRW (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Curexo Inc (060280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Curexo Inc it is 846.16 KRW per share (as of Nov 7, 2026), against a price of 6,570 KRW. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Curexo Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 060280 trades above its calculated fair value: price 6,570 KRW, fair value 846.16 KRW, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 060280?
No. The price is what the market pays today (6,570 KRW); the fair value is what the company's own numbers justify (846.16 KRW). For Curexo Inc the two are 5,724 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Curexo Inc worth?
The market values Curexo Inc at about 306B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 6,570 KRW; our models calculate a fair value of 846.16 KRW per share.
What do the bullish and bearish scenarios say about 060280?
Our models span a range for Curexo Inc: cautious scenario 806.28 KRW, base 846.16 KRW, optimistic 878.19 KRW per share (as of Nov 7, 2026, price 6,570 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 060280 from its 52-week high?
Curexo Inc trades at 6,570 KRW, about 68% below its 52-week high of 20,350 KRW and at the low of 6,570 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 846.16 KRW is for.
Which stocks are comparable to Curexo Inc?
From the same area (Consumer Non-Cyclicals) we also value PGOLD, Gimat Magazacilik Sanayi Ve Ticaret A.S., KEEPR, FRUIT, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Curexo Inc stock attractive at the current price?
The data as of Nov 7, 2026: price 6,570 KRW, calculated fair value 846.16 KRW (−87%), Quality Score 61/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 060280 calculated?
We run Curexo Inc through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 846.16 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Curexo Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Curexo Inc (060280)?
The closing price on Nov 6, 2026 was 6,570 KRW. Our model-based fair value is 846.16 KRW, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Curexo Inc right now?
The price sits above even our optimistic bull case (878.19 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (806.28 KRW to 878.19 KRW), unusually little disagreement for a valuation.
Key figures of Curexo Inc
How large is the market capitalisation of Curexo Inc (060280)?
The market capitalisation of Curexo Inc is 306B KRW (≈ $224M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Curexo Inc (060280)?
The price-to-sales ratio of Curexo Inc is 11.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Curexo Inc (060280)?
The net margin of Curexo Inc is −58.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Curexo Inc (060280)?
The return on equity (ROE) of Curexo Inc is −744% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Curexo Inc (060280)?
On an EBIT basis the return on assets of Curexo Inc is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Curexo Inc (060280)?
The operating margin of Curexo Inc is −153% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Curexo Inc (060280)?
Revenue at Curexo Inc is growing +4.3% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Curexo Inc (060280) generate?
The free cash flow of Curexo Inc is −13.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Curexo Inc (060280) carry?
The net debt of Curexo Inc is 5.2B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Curexo Inc in the live analysis
One click puts Curexo Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026